Clinical trials: Peanut Hypersensitivity

Food Allergy

Long-term Extension Study of Ligelizumab in Food Allergy

• Terminated
• Age: 6 to 57 years
• Phase 3
• Results posted

This was an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who completed a ligelizumab Phase III study in food allergy.

Trial name

NCT05678959

Testing

Ligelizumab 120 mg, Ligelizumab 240 mg

Where

49 sites in United States, Australia and 7 more

Volunteers

163 people

Sponsor

Novartis Pharmaceuticals